PIK3CA and head and neck squamous cell carcinoma: In the present study, we demonstrated that endogenous PIK3CA-MT HNSCC cell lines show an enhanced sensitivity to combined EGFR–NSAID treatment relative to PIK3CA-WT cell lines.